Clinical Activity of Crizotinib in Lung Adenocarcinoma Harboring a Rare ZCCHC8-ROS1 Fusion

被引：7
|
作者：
Hicks, J. Kevin [1 ]
Boyle, Theresa [2 ]
Albacker, Lee A. [3 ]
Madison, Russell [3 ]
Frampton, Garrett [3 ]
Creelan, Benjamin C. [2 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, DeBartolo Family Personalized Med Inst, Dept Individualized Canc Management, Tampa, FL USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL USA
[3] Fdn Med, Cambridge, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 08期
关键词：
ROS1;
D O I：
10.1016/j.jtho.2018.03.028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E148 / E150
页数：3
相关论文
共 50 条
  • [1] Clinical activity of crizotinib in lung adenocarcinoma harboring a HLA_A-ROS1 rearrangement: A case report
    Kinoshita, Ryosuke
    Nakao, Makoto
    Kiyotoshi, Hiroko
    Hayashi, Syuntaro
    Sugihara, Masahiro
    Hirata, Yuya
    Kuriyama, Mamiko
    Takeda, Norihisa
    Muramatsu, Hideki
    [J]. ONCOLOGY LETTERS, 2023, 26 (06)
  • [2] A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib
    Zhu, You-cai
    Wang, Wen-xian
    Xu, Chun-wei
    Zhuang, Wu
    Song, Zheng-bo
    Du, Kai-qi
    Chen, Gang
    Lv, Tang-feng
    Song, Yong
    [J]. CANCER BIOLOGY & THERAPY, 2018, 19 (12) : 1097 - 1101
  • [3] Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant
    Zhao, Zheng
    Song, Zhangjun
    Wang, Xuwei
    Sun, Haifeng
    Yang, Xiaomin
    Yuan, Yong
    Yu, Pan
    [J]. ONCOTARGETS AND THERAPY, 2017, 10 : 4129 - 4133
  • [4] Identification of a Rare BAIAP2-ROS1 Fusion and Clinical Benefit of Crizotinib in the Treatment of Advanced Lung Adenocarcinoma: A Case Report
    Lin, YunYu
    Lei, Yan
    Li, LinWei
    Su, Xiaoxing
    Tian, Qiqi
    Wu, Wendy
    [J]. ONCOTARGETS AND THERAPY, 2022, 15 : 831 - 836
  • [5] Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib
    Liu, Yutao
    Liu, Tianfeng
    Li, Nan
    Wang, Tao
    Pu, Yue
    Lin, Rui
    [J]. LUNG CANCER, 2019, 129 : 92 - 94
  • [6] Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
    Yongchang Zhang
    Zhe Huang
    Liang Zeng
    Xiangyu Zhang
    Yizhi Li
    Qinqin Xu
    Haiyan Yang
    Analyn Lizaso
    Chunwei Xu
    Jun Liu
    Wenxian Wang
    Zhengbo Song
    Sai-Hong Ignatius Ou
    Nong Yang
    [J]. npj Precision Oncology, 6
  • [7] Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
    Zhang, Yongchang
    Huang, Zhe
    Zeng, Liang
    Zhang, Xiangyu
    Li, Yizhi
    Xu, Qinqin
    Yang, Haiyan
    Lizaso, Analyn
    Xu, Chunwei
    Liu, Jun
    Wang, Wenxian
    Song, Zhengbo
    Ou, Sai-Hong Ignatius
    Yang, Nong
    [J]. NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [8] Identification of a novel NPM1-ROS1 fusion in a lung adenocarcinoma and sensitive to crizotinib treatment
    Ma, Hongxia
    Zhang, Qian
    Duan, Qianqian
    Zhang, Qin
    Li, Fengsen
    [J]. LUNG CANCER, 2021, 152 : 196 - 198
  • [9] ROS1-ADGRG6: A Novel ROS1 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Crizotinib
    Li, X.
    Xu, C.
    Xu, S.
    Wang, W.
    Ye, J.
    Zhu, Y.
    Ge, T.
    Fang, M.
    Lv, T.
    Song, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1049 - S1049
  • [10] Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report
    Shu, Yun
    Li, Hui
    Shang, Hongjuan
    Chen, Jun
    Su, Xiaoxing
    Le, Wei
    Lei, Yan
    Tao, Liming
    Zou, Cailiang
    Wu, Wendy
    [J]. ONCOTARGETS AND THERAPY, 2020, 13 : 10387 - 10391
12345